COVID-19NCT06999018
Humeral Shaft Fractures : Outcomes of Straight Percutaneous Intramedullary Nailing With Dynamic Distal Locking
An observational study of COVID-19 and Coronavirus Infections, run by Centre Hospitalier de Saint-Denis at 1 site in France.
Trial summary
This study looks at how many healthcare workers at CHSD have developed antibodies against COVID-19 after the second and third waves of the pandemic and following vaccination. By testing blood samples, we want to understand how well healthcare workers are protected, which work areas might be more at risk, and how… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COVID-19, Coronavirus Infections, Seroprevalence
- How many people
- 76 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2020to 1 Jan 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: The study population consists of adult patients who underwent surgical treatment for closed, isolated, and displaced fractures of the humeral shaft. These patients were treated with percutaneous anterograde intramedullary nailing using dynamic distal locking between January 2008 and June 2018. The population includes both men and women, with a mean age of approximately 53 years. Only patients with fractures classified as type A, B, or C according to the AO/OTA classification and who were available for follow-up evaluation were included. Patients with open fractures, non-isolated or non-displaced fractures, or those lost to follow-up were excluded.
Who may be able to join
- Patients operated between January 2008 and June 2018
- Closed, isolated, displaced fractures of the humeral shaft
- Treatment by percutaneous anterograde intramedullary nailing with dynamic distal locking
- Availability for follow-up and evaluation (e.g., Constant score assessment in June 2018)
Who cannot join
- Open fractures
- Fractures that are not isolated or not displaced
- Patients lost to follow-up at the June 2018 evaluation (18 excluded)
- Lack of Constant score evaluation (patients not reviewed)
Trial locations and contacts
1 site in 1 country.
About this study
This study looks at how many healthcare workers at CHSD have developed antibodies against COVID-19 after the second and third waves of the pandemic and following vaccination. By testing blood samples, we want to understand how well healthcare workers are protected, which work areas might be more at risk, and how immunity changes over time after infection or vaccination.
- Medical subject headings
- COVID-19, Coronavirus Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
The seroprevalence of SARS-CoV-2 antibodies among healthcare workers at CHSD following COVID-19 vaccination and previous infection.
Measured: January 2008 - June 2018
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2025
- Study start1 Jan 2020
- Primary completion1 Jan 2021
- Study completion1 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 76 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier de Saint-Denis
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06999018
- Sponsor's protocol ID
- 0013_HUMERUS
- Status last verified
- May 2025
- First submitted
- 22 May 2025
- Last updated
- 31 May 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Humeral Shaft Fractures : Outcomes of Straight Percutaneous Intramedullary Nailing With Dynamic Distal Locking
- ClinicalTrials.gov ID
- NCT06999018
- Acronym / sponsor ID
- 0013_HUMERUS
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 76 participants (actual)
- Lead sponsor
- Centre Hospitalier de Saint-DenisUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Jan 2021 (actual)
- Study completion
- 1 Jan 2021 (actual)
- First posted
- 31 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at how many healthcare workers at CHSD have developed antibodies against COVID-19 after the second and third waves of the pandemic and following vaccination. By testing blood samples, we want to understand how well healthcare workers are protected, which work areas might be more at risk, and how immunity changes over time after infection or vaccination.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- The study population consists of adult patients who underwent surgical treatment for closed, isolated, and displaced fractures of the humeral shaft. These patients were treated with percutaneous anterograde intramedullary nailing using dynamic distal locking between January 2008 and June 2018. The population includes both men and women, with a mean age of approximately 53 years. Only patients with fractures classified as type A, B, or C according to the AO/OTA classification and who were available for follow-up evaluation were included. Patients with open fractures, non-isolated or non-displaced fractures, or those lost to follow-up were excluded.
Key inclusion criteria (4 listed)
- Patients operated between January 2008 and June 2018
- Closed, isolated, displaced fractures of the humeral shaft
- Treatment by percutaneous anterograde intramedullary nailing with dynamic distal locking
- Availability for follow-up and evaluation (e.g., Constant score assessment in June 2018)
Key exclusion criteria (4 listed)
- Open fractures
- Fractures that are not isolated or not displaced
- Patients lost to follow-up at the June 2018 evaluation (18 excluded)
- Lack of Constant score evaluation (patients not reviewed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The seroprevalence of SARS-CoV-2 antibodies among healthcare workers at CHSD following COVID-19 vaccination and previous infection.
Time frame: January 2008 - June 2018
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2025.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Coronavirus Infections, run by Centre Hospitalier de Saint-Denis at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The seroprevalence of SARS-CoV-2 antibodies among healthcare workers at CHSD following COVID-19 vaccination and previous infection. (time frame: January 2008 - June 2018). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2025.